HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
21 hedge funds and large institutions have $41.5M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$18.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.55M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$6.57M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$6.55M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.85M |
Top Sellers
HTGM Hedge Fund Activity: Q2 2015 in Review
21 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2015, worth a combined $41.5M.
Buyers outnumbered sellers: 21 funds opened new HTGM positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $18.2M.
- 21 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $41.5M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2015.
- 21 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2015 and 0 closed out, a net change of +21 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q2 2015 was Novo Holdings A/S, an estimated $18.2M added.
Based on aggregated 13F filings for Q2 2015.